ArticleJournal of neuroscience research2026
DKK1 Targeting in Corneal Schwann Cells Rescues Axonal Regeneration and Mechanosensory Function After Corneal Injury.
Article in Journal of neuroscience research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- DKK1 Targeting in Corneal Schwann Cells Rescues Axonal Regeneration and Mechanosensory Function After Corneal Injury.Journal of neuroscience research · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Stromal nerves regulate the sensory functions of the cornea, which can be disrupted by surgical, traumatic, or chemical injuries. Corneal Schwann cells (cSCs) ensheath axons to provide trophic support, but their role in axonal regeneration is still unexplored. We utilized the proteolipid protein 1-enhanced green fluorescent protein (Plp1-eGFP) reporter mice to investigate cSCs in two models of corneal nerve injury: the corneal micropocket injury (CMI) model, which causes focal stromal axonal severance, and acute exposure to nitrogen mustard (NM), which results in blunt damage across the entire cornea and limbal tissue. After CMI, the cSC network declined rapidly over 7 days post-injury (dpi) but recovered to levels of uninjured controls by 14 dpi with sprouting at both the injury and collateral areas. Axons remained significantly lower than cSCs, compromising mechanosensory functions. The NM injury led to a sustained cSC and axonal deficit with persistent mechanosensory loss through 14 dpi. Previously, we identified Dickkopf-related protein 1 (DKK1) as a novel candidate gene expressed in cSCs. In this study, we developed a micellar formulation RM4404 incorporating a small-molecule DKK1 inhibitor for topical application and tested the therapeutic potential of this drug in both injury models. Application of RM4404 during the cSC regenerative phase (7-14 dpi) enhanced cSC repair and significantly improved axonal regeneration with restoration of mechanosensory function in both injury paradigms. These findings identify a promising DKK1-targeted therapy that promotes cSC repair, enhances corneal nerve regeneration, and restores sensory function in models of corneal injury.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.